Strategic Partnerships PolyActiva has formed a strategic collaboration with RareSight to develop breakthrough treatments for rare pediatric retinal diseases, indicating a potential channel for co-development deals, licensing opportunities, and joint clinical programs with specialty ophthalmology-focused organizations.

Clinical Stage Advantage As a clinical-stage ophthalmology company with a proprietary slow-release polymeric prodrug technology, PolyActiva is pursuing long-term, site-specific ocular drug delivery, which can attract interest from larger pharma players seeking innovative, differentiated eye implants to expand their glaucoma and retinal disease portfolios.

Significant Funding Recent Series C funding of around AU$40 million and a total funding of AU$38 million signals investor validation and robust runway for expansion, supporting outreach to potential strategic investors, co-development partners, and contract manufacturing discussions.

Manufacturing Momentum Funding aims include enhancing local manufacturing for glaucoma implants, presenting an opportunity to engage contract development and manufacturing organizations (CDMOs) and supply-chain partners for scale-up, regulatory-ready production, and regional commercialization strategies.

Industry Engagement Active participation in industry events such as Eyecelerator at AAO 2025 and ongoing communications about next-generation ocular micro-implant tech create openings for keynote-style sponsorships, speaking engagements, and early-access collaborations with eye care providers and research networks.